|By PR Newswire||
|March 11, 2014 10:00 AM EDT||
LONDON, March 11, 2014 /PRNewswire/ --
Antibacterials - new analysis showing business trends, R&D, and revenue forecasts
What is the future of medicines treating bacterial infections? For those drugs you get new sales predictions, also exploring research and development. Those treatments hold high potentials. There you assess results, progress, therapies, and opportunities.
Knowledge facilitates success. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. There you stay ahead in data on microbial diseases, finding commercial prospects to benefit your influence.
Read on to explore antibiotics for human healthcare, seeing how high sales can go.
Forecasts to 2024 and other analyses explain and predict that antimicrobials market
Why miss data you need? Why struggle to find it, or fall behind? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find recent results, growth rates, market shares, and discussions.
Also you see the potential of research and development. That study gives 126 tables, 102 charts, and interviews with three companies.
There you assess the future of antibacterials, hearing how patients, doctors, and pharma companies can benefit. You stay ahead, then, finding where money lies, assessing the most lucrative selling prospects.
And the following sections show how that new investigation helps your research, analyses and decisions. See there how you could benefit your authority and save time, staying ahead.
Sales predictions for the world antibiotics market and submarkets
What is that biomedical industry's potential? What are the secrets of its progress? Discover in our report overall world revenue to 2024 for those bacteria-treating agents.
Also find individual revenue predictions to 2024 for six therapeutic submarkets at world level:
• Other treatments for bacterial infections.
There you explore prospects from 2014, hearing where you could profit from novel agents and generic drugs (generics). Investigate competition, developments, and rising sales.
That study also predicts and discusses leading medicines' sales potentials
To see an exec summary of this report please email Sara Peerun on [email protected] .
Revenue predictions for leading and expected products
How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 43 products - marketed agents and drugs awaiting launch.
You assess top products, including these:
• Generic amoxicillin
There you find medicines and years with highest predicted sales. Also you examine competitors and get an understanding of recent challenges, trends, and outlooks.
For that overall market, the report also shows geographical revenue predictions.
National markets - what are the demands for antibacterial therapies?
In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2014 to 2024. See where and how.
Our analyses show you individual revenue forecasts to 2024 for a regional block and 12 national markets:
• United States (US)
• European Union (EU) - also with separate forecasts for France, Germany, the UK, Italy, and Spain (EU5 countries)
• South Korea
• The BRIC nations - Brazil, Russia, India, and China.
For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for fighting bacterial infections, also assessing the expected financial gains.
And what events change that industry? Our work shows you, discussing trends, challenges and opportunities.
Market forces and issues - what affects antibiotic developers, producers and sellers?
The report shows you issues and events affecting that industry and market from 2014, including these:
• Antibacterial drug consumption statistics at national level
• Incidences of urinary tract, skin, and respiratory tract infections from bacteria
• Generic competition for leading brands - effects of patent expiries
• Prescription control to reduce bacterial resistance, including that of methicillin-resistant S. aureus (MRSA)
• Encouraging antibiotic drug discovery and development - push and pull incentives, inc. public-private collaborations.
And you explore these influences, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other new drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies.
Discover what the future holds. There you explore political, economic, social, and technological questions. See, too, how R&D lets companies benefit patients.
There you find what stimulates and restrains players in that sector, and affects its results.
To see an exec summary of this report please email Sara Peerun on [email protected]
Analysis of top companies and potential for market growth - what revenue is possible?
From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from bacteria-treating drugs.
So what happens next? Our study predicts that world market will reach $42.75bn in 2018, with further expansion to 2024.
That work also explores activities and potentials of these companies, among others:
• GlaxoSmithKline (GSK)
• Merck & Co.
• Cubist Pharmaceuticals
• Daiichi Sankyo.
R&D in that industry holds strengths, and from 2014 opportunity arises. Patients, payers, and companies will benefit. Discover what is possible.
And you will be able to see how that market can perform, staying ahead in knowledge and benefiting your reputation for commercial insight.
Ways Antibacterial Drugs: World Industry and Market Prospects 2014-2024 helps you
In particular, that new investigation gives you this information:
• Revenues there to 2024 at world level, for 6 submarkets, and 43 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.
Knowledge found nowhere else, helping your searches, analyses, and planning
Our study gives independent data. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.
With that original research and analysis you are less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort. And also help your plans, decisions, influence, and competing.
The new report shows commercial potentials of medicines for human infective diseases. There you explore trends and R&D, and investigate future sales. So avoid missing out - please order now.
Companies Listed in this report:
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA)
Brazilian National Health Surveillance Agency
Centers for Disease Control and Prevention (CDC)
Chinese Ministry of Health
Dr. Reddy's Laboratories
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Fitch Ratings Agency
Food and Drug Administration (US FDA)
Hi Tech Pharma
Indian Ministry of Health and Family Welfare
Itochu Chemical Frontier
Japanese Ministry of Health Labor and Welfare
Johns Hopkins University School of Medicine
Johnson & Johnson
Medicines and Healthcare Products Regulatory Agency
Meiji Seika Pharma
Merck & Co.
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Institute for Health and Clinical Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Procter & Gamble
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Sistema Nacional de Gerenciamento de Produtos Controlados
Teva Pharmaceutical Industries
The Medicines Company
University of Leicester
University of Michigan
US Department of Health
World Health Organization (WHO)
Zhejiang Medicine Company
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel : +44(0)20-7336-6100
Container technology is shaping the future of DevOps and it’s also changing the way organizations think about application development. With the rise of mobile applications in the enterprise, businesses are abandoning year-long development cycles and embracing technologies that enable rapid development and continuous deployment of apps. In his session at DevOps Summit, Kurt Collins, Developer Evangelist at Built.io, examined how Docker has evolved into a highly effective tool for application del...
Nov. 26, 2015 07:00 PM EST Reads: 320
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Nov. 26, 2015 04:00 PM EST Reads: 375
Internet of @ThingsExpo, taking place June 7-9, 2016 at Javits Center, New York City and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
Nov. 26, 2015 03:30 PM EST Reads: 521
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Y...
Nov. 26, 2015 03:30 PM EST Reads: 441
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Nov. 26, 2015 03:15 PM EST Reads: 517
We are rapidly moving to a brave new world of interconnected smart homes, cars, offices and factories known as the Internet of Things (IoT). Sensors and monitoring devices will touch every part of our lives. Let's take a closer look at the Internet of Things. The Internet of Things is a worldwide network of objects and devices connected to the Internet. They are electronics, sensors, software and more. These objects connect to the Internet and can be controlled remotely via apps and programs. ...
Nov. 26, 2015 02:15 PM EST Reads: 496
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving t...
Nov. 26, 2015 01:00 PM EST Reads: 389
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Nov. 26, 2015 01:00 PM EST Reads: 288
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Nov. 26, 2015 12:00 PM EST Reads: 146
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
Nov. 26, 2015 11:30 AM EST Reads: 119
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Nov. 26, 2015 11:00 AM EST Reads: 443
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
Nov. 26, 2015 11:00 AM EST Reads: 122
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Nov. 26, 2015 10:00 AM EST Reads: 285
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
Nov. 26, 2015 09:45 AM EST Reads: 368
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Nov. 26, 2015 09:30 AM EST Reads: 374